Articles related to SOLID TUMORS

Afamitresgene autoleucel offers a novel approach to treating metastatic synovial sarcoma, with an overall response rate of 43.2% in clinical trials, providing a much-needed alternative to traditional chemotherapy.

A 51-year-old woman’s case of Meigs’ syndrome underscores the importance of distinguishing this benign condition from ovarian cancer, emphasizing the resolution of symptoms following the excision of the ovarian fibroma.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Understanding the nuances in diagnosing soft tissue masses is crucial for healthcare providers, as misdiagnosis can lead to delays in treatment and potentially worsen patient outcomes.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.